VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
74
PAGES
175
EDITION
18
PRICE
USD $5600
With the Global Economy Walking the Tightrope, It's the Numbers that Help Understand this Uncertain World.
INSIDER ACCESS PRIVILEGES
KEY DIFFERENTIATORS
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Biosimilars: An Introductory Prelude |
Recent Market Activity |
World Healthcare Sector Gears Up for Biosimilar Wave |
Biosimilars Offer Great Promise Despite Challenges |
The US & Europe Drive Momentum in Worldwide Biosimilars Sales |
Emerging Markets also Offer Robust Growth Opportunities |
R&D Funding: Crucial for Future Expansion of Biosimilars Market |
Prevailing Economic Scenario Favors Funding Pattern |
Global Competitor Market Shares |
Biosimilars Competitor Market Share Scenario Worldwide (in %): 2018 & 2029 |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
Allergan Plc (Ireland) |
Amgen, Inc. (USA) |
Biocon Ltd. (India) |
Biopartners GmbH (Switzerland) |
Boehringer Ingelheim International GmbH (Germany) |
Celltrion, Inc. (South Korea) |
Dr. Reddy's Laboratories Ltd. (India) |
Eli Lilly and Company (USA) |
Fresenius Kabi (Germany) |
Intas Pharmaceuticals Ltd. (India) |
Mylan N.V. (USA) |
Pfizer, Inc. (USA) |
Samsung Bioepis Co., Ltd. (Korea) |
Sandoz International GmbH (Germany) |
STADA Arzneimittel AG (Germany) |
Teva Pharmaceutical Industries Ltd. (Israel) |
3. MARKET TRENDS & DRIVERS |
Slew of Product Approvals Scale Up Market Revenues |
Biosimilar Approvals in Europe (as of H1 2018) |
Biosimilar Approvals in the US (as of H1 2018) |
Pipeline Biosimilar Products in the US (as of H1 2018) |
Biosimilar Approvals in South Korea (as of H1 2018) |
Patent Expiry of Major Biopharmaceutical Drugs Leads Way for Biosimilars |
Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe |
Cost Containment Measures Put Focus on Biosimilars |
High Cost of Biologics - Favorable for Biosimilars |
Efforts to Push Up Biosimilar Adoption Aid Market Expansion |
Increasing Share of Biotech Drugs to Drive Biosimilars Market |
Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues |
Specific Guidelines for Biosimilars in Various Countries with Year of Publication |
Biosimilars Regulatory Agencies in Select Regional Markets |
Improvement in Nomenclature & Interchangeability Enhance Appeal & Image of Biosimilars |
Human Insulin Biosimilars Eye Potential Opportunities |
Monoclonal Antibodies - A Key Segment for Biosimilars |
Approved Monoclonal Antibodies (2014-2017) |
Rituximab Biosimilars to Proliferate the Market |
Growing Incidence of Chronic Diseases & Ageing Population Widen Prospects for Biosimilars |
Growing Biosimilars Market - A Clear Advantage for Bioseparation Technologies |
Growth Restraints |
Lack of Uniform Regulations |
High Lead-time |
High Manufacturing Costs |
Difficulties in Delivery & Commercialization |
Automatic Substitution |
Biobetters: A Potential Industry Challenge |
Other Impediments to Market Acceptance |
4. GLOBAL MARKET PERSPECTIVE |
Biosimilars Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
Biosimilars Market Share Shift across Key Geographies Worldwide: 2019 VS 2025 |
Recombinant Non-glycosylated Proteins (Product Type) World Market by Region/Country in US$ Million: 2018 to 2025 |
Recombinant Non-glycosylated Proteins (Product Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2019 VS 2025 |
Recombinant Glycosylated Proteins (Product Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 |
Recombinant Glycosylated Proteins (Product Type) Market Sales Breakdown by Region/Country in Percentage: 2019 VS 2025 |
Recombinant Peptides (Product Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 |
Recombinant Peptides (Product Type) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025 |
Blood Disorders (Disease) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 |
Blood Disorders (Disease) Market Share Breakdown by Region/Country: 2019 VS 2025 |
Oncology (Disease) World Market by Region/Country in US$ Million: 2018 to 2025 |
Oncology (Disease) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025 |
Chronic Diseases (Disease) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 |
Chronic Diseases (Disease) Market Percentage Share Distribution by Region/Country: 2019 VS 2025 |
Autoimmune Diseases (Disease) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 |
Autoimmune Diseases (Disease) Market Share Distribution in Percentage by Region/Country: 2019 VS 2025 |
Other Diseases (Disease) World Market by Region/Country in US$ Million: 2018 to 2025 |
Other Diseases (Disease) Market Share Breakdown of Worldwide Sales by Region/Country: 2019 VS 2025 |
III. MARKET ANALYSIS |
GEOGRAPHIC MARKET ANALYSIS |
United States |
Market Facts & Figures |
US Biosimilars Market Share (in %) by Company: 2018 & 2025 |
United States Biosimilars Market Estimates and Projections in US$ Million by Product Type: 2018 to 2025 |
United States Biosimilars Market Share Breakdown by Product Type: 2019 VS 2025 |
United States Biosimilars Market Estimates and Projections in US$ Million by Disease: 2018 to 2025 |
United States Biosimilars Market Share Breakdown by Disease: 2019 VS 2025 |
Canada |
Canadian Biosimilars Market Estimates and Forecasts in US$ Million by Product Type: 2018 to 2025 |
Biosimilars Market in Canada: Percentage Share Breakdown of Sales by Product Type for 2019 and 2025 |
Canadian Biosimilars Market Estimates and Forecasts in US$ Million by Disease: 2018 to 2025 |
Biosimilars Market in Canada: Percentage Share Breakdown of Sales by Disease for 2019 and 2025 |
Japan |
Japanese Market for Biosimilars: Annual Sales Estimates and Projections in US$ Million by Product Type for the Period 2018-2025 |
Japanese Biosimilars Market Share Analysis by Product Type: 2019 VS 2025 |
Japanese Market for Biosimilars: Annual Sales Estimates and Projections in US$ Million by Disease for the Period 2018-2025 |
Japanese Biosimilars Market Share Analysis by Disease: 2019 VS 2025 |
China |
Chinese Biosimilars Market Growth Prospects in US$ Million by Product Type for the Period 2018-2025 |
Chinese Biosimilars Market by Product Type: Percentage Breakdown of Sales for 2019 and 2025 |
Chinese Biosimilars Market Growth Prospects in US$ Million by Disease for the Period 2018-2025 |
Chinese Biosimilars Market by Disease: Percentage Breakdown of Sales for 2019 and 2025 |
Europe |
Market Facts & Figures |
European Biosimilars Market: Competitor Market Share Scenario (in %) for 2018 & 2025 |
European Biosimilars Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
European Biosimilars Market Share Shift by Region/Country: 2019 VS 2025 |
European Biosimilars Market Estimates and Forecasts in US$ Million by Product Type: 2018-2025 |
European Biosimilars Market Share Breakdown by Product Type: 2019 VS 2025 |
European Biosimilars Market Estimates and Forecasts in US$ Million by Disease: 2018-2025 |
European Biosimilars Market Share Breakdown by Disease: 2019 VS 2025 |
France |
Biosimilars Market in France by Product Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
French Biosimilars Market Share Analysis by Product Type: 2019 VS 2025 |
Biosimilars Market in France by Disease: Estimates and Projections in US$ Million for the Period 2018-2025 |
French Biosimilars Market Share Analysis by Disease: 2019 VS 2025 |
Germany |
Biosimilars Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Product Type for the Period 2018-2025 |
German Biosimilars Market Share Breakdown by Product Type: 2019 VS 2025 |
Biosimilars Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Disease for the Period 2018-2025 |
German Biosimilars Market Share Breakdown by Disease: 2019 VS 2025 |
Italy |
Italian Biosimilars Market Growth Prospects in US$ Million by Product Type for the Period 2018-2025 |
Italian Biosimilars Market by Product Type: Percentage Breakdown of Sales for 2019 and 2025 |
Italian Biosimilars Market Growth Prospects in US$ Million by Disease for the Period 2018-2025 |
Italian Biosimilars Market by Disease: Percentage Breakdown of Sales for 2019 and 2025 |
United Kingdom |
United Kingdom Market for Biosimilars: Annual Sales Estimates and Projections in US$ Million by Product Type for the Period 2018-2025 |
United Kingdom Biosimilars Market Share Analysis by Product Type: 2019 VS 2025 |
United Kingdom Market for Biosimilars: Annual Sales Estimates and Projections in US$ Million by Disease for the Period 2018-2025 |
United Kingdom Biosimilars Market Share Analysis by Disease: 2019 VS 2025 |
Rest of Europe |
Rest of Europe Biosimilars Market Estimates and Forecasts in US$ Million by Product Type: 2018-2025 |
Rest of Europe Biosimilars Market Share Breakdown by Product Type: 2019 VS 2025 |
Rest of Europe Biosimilars Market Estimates and Forecasts in US$ Million by Disease: 2018-2025 |
Rest of Europe Biosimilars Market Share Breakdown by Disease: 2019 VS 2025 |
Asia-Pacific |
Biosimilars Market in Asia-Pacific by Product Type: Estimates and Projections in US$ Million for the Period 2018-2025 |
Asia-Pacific Biosimilars Market Share Analysis by Product Type: 2019 VS 2025 |
Biosimilars Market in Asia-Pacific by Disease: Estimates and Projections in US$ Million for the Period 2018-2025 |
Asia-Pacific Biosimilars Market Share Analysis by Disease: 2019 VS 2025 |
Rest of World |
Rest of World Biosimilars Market Estimates and Forecasts in US$ Million by Product Type: 2018 to 2025 |
Biosimilars Market in Rest of World: Percentage Share Breakdown of Sales by Product Type for 2019 and 2025 |
Rest of World Biosimilars Market Estimates and Forecasts in US$ Million by Disease: 2018 to 2025 |
Biosimilars Market in Rest of World: Percentage Share Breakdown of Sales by Disease for 2019 and 2025 |
IV. COMPETITION |
Total Companies Profiled : 71 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com